PubMed Health treatment related to Hemolytic Anemia: 62
Treatments for hemolytic anemia include blood transfusions , medicines, plasmapheresis (PLAZ-meh-feh-RE-sis), surgery , blood and marrow stem cell transplants , and lifestyle changes. People who have mild hemolytic anemia may not need treatment , as long as the condition doesn't worsen. People who have severe hemolytic anemia usually need ongoing treatment. Severe hemolytic anemia can be fatal if it's not properly treated.
Drugs for Hemolytic Anemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 201)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Ribavirin |
Approved |
Phase 4 |
|
36791-04-5 |
37542 |
Synonyms:
1-.beta.-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide
1-b-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-b-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
36791-04-5
437710-49-1
66510-90-5
AA-504/07617051
AB00430481
AC1L1XXZ
AC1Q1IDC
AC1Q4ZGS
AKOS001715163
BB_NC-0567
BPBio1_001195
BRN 0892462
BSPBio_001085
BSPBio_003352
CHEMBL1643
CID37542
Copegus
Copegus (TN)
Cotronak
C-Virin
D00423
DB00811
Dermatech brand OF ribavirin
DivK1c_000782
DRG-0028
Drug: Ribavirin
Essex brand OF ribavirin
EU-0101063
FT-0082885
Grossman brand OF ribavirin
HMS2090L15
HMS2094O09
HMS502H04
HSDB 6513
ICN brand OF ribavirin
ICN-1229
IDI1_000782
KBio1_000782
KBio2_002328
KBio2_004896
KBio2_007464
KBio3_002854
KBioGR_001804
KBioSS_002331
KS-1104
Lopac0_001063
LS-1241
Merck brand OF ribavirin
MLS000028486
MLS002222317
MolPort-002-507-104
MolPort-002-885-856
NCGC00090726-01
NCGC00090726-03
NCGC00090726-04
NCGC00090726-05
NCGC00090726-06
NCGC00090726-07
|
NINDS_000782
NSC 163039
NSC163039
Pfizer brand OF ribavirin
Prestwick3_000993
R 9644
R-964
R9644_SIGMA
Ravanex
RBV
Rebetol
Rebetol (TN)
Rebetron
Rebretron
RG-964
Ribacine
Ribamide
Ribamidil
Ribamidyl
Ribasphere
Ribasphere (TN)
Ribav
RIBAV
ribavirin
Ribavirin
Ribavirin (JAN/USP/INN)
Ribavirin [USAN:INN]
Ribavirin Capsules
Ribavirin merck brand
Ribavirin Triphosphate
Ribavirina
Ribavirina [INN-Spanish]
Ribavirine
Ribavirine [INN-French]
Ribavirin-TP
Ribavirinum
Ribavirinum [INN-Latin]
Ribovirin
Ro 20-9963/000
Ro-20-9963
RTC
RTCA
RTP
S2504_Selleck
SCH 18908
SMP1_000261
SMR000058315
Spectrum_001826
SPECTRUM1503938
Spectrum3_001876
Spectrum4_001252
Spectrum5_002075
SR-01000076112-3
Three rivers pharmaceuticals brand OF ribavirin
Tribavirin
UNII-49717AWG6K
Varazid
Vilona
Viramid
Viramide
Virazid
Virazide
Virazole
Virazole (Ribavirin) Inhalation Solution
Virazole (TN)
Virazole 5'-triphosphate
ZINC01035331
|
|
2 |
|
Peginterferon alfa-2a |
Approved, Investigational |
Phase 4 |
|
198153-51-4 |
5360545 |
Synonyms:
198153-51-4
D02747
Pegasys
Pegasys (TN)
PEG-IFN alfa-2A
Peginterferon alfa-2a
PEG-Interferon alfa-2A
|
Peginterferon alfa-2a (genetical recombination)
Peginterferon alfa-2a (genetical recombination) (JAN)
Peginterferon alfa-2a (USAN/INN)
Pegylated Interfeaon alfa-2A
Pegylated interferon alfa-2a
Pegylated interferon alpha-2a
Pegylated-interferon alfa 2a
|
|
3 |
|
Lumefantrine |
Approved |
Phase 4 |
|
82186-77-4 |
6437380 |
Synonyms:
(+-)-2,7-dichloro-9-((Z)-P-Chlorobenzylidene)-a-((dibutylamino)methyl)fluorene-4-methanol
(+-)-2,7-dichloro-9-((Z)-P-Chlorobenzylidene)-alpha-((dibutylamino)methyl)fluorene-4-methanol
(+-)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-alpha((dibutylamino)methyl)fluorene-4-methanol
(+-)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-alpha-((dibutylamino)methyl)fluorene-4-methanol
(+-)-2,7-dichloro-9-((Z)-P-Chlorobenzylidene)-α-((dibutylamino)methyl)fluorene-4-methanol
(±)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-α-((dibutylamino)methyl)fluorene-4-methanol
120583-69-9
2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-(4-chlorobenzylidene)-9H-fluoren-4-yl]ethanol
2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]fluoren-4-yl]ethanol
2-dibutylamino-1-[2,7-dichloro-9-(4-chloro-Benzylidene)-9H-fluoren-4-yl]-ethanol
2-Dibutylamino-1-[2,7-dichloro-9-(4-chloro-benzylidene)-9H-fluoren-4-yl]-ethanol
2-dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-9H-fluoren-4-yl}-ethanol
2-Dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-9H-fluoren-4-yl}-ethanol
82186-77-4
AC1O5NKD
AC-4542
benflumetol
Benflumetol
Benflumetol, (-)-isomer
Benflumetol, (+)-isomer
|
Benflumetol, (+-)-isomer
Bio-0132
C30H32Cl3NO
CHEBI:156095
CHEMBL38827
CID6437380
Coartem
D03821
DB06708
dl-Benflumelol
DL-Benflumelol
HSDB 7210
I14-7746
LS-177674
Lumefantrine
Lumefantrine (INN)
Lumefantrine [INN:BAN]
MolPort-006-394-826
NCGC00167490-01
UNII-F38R0JR742
|
|
4 |
|
Artemether |
Approved |
Phase 4 |
|
71963-77-4 |
68911 9796294 119380 |
Synonyms:
( )-alpha-Artemether
(1R,4S,5R,8S,9R,10S,12R,13R)-10-methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecane
(1R,4S,5R,8S,9R,10S,12R,13R)-10-Methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecane
(3alpha,5abeta,6beta,8abeta,9alpha,10beta,12beta,12aR*)-isomer of artemether
(3r,5as,6r,8as,9r,10r,12r,12ar)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene
(3R,5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepine
(3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin
(5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene
.beta.-Artemether
.beta.-Dihydroartemisinin methyl ether
.beta.-Methylether of 11-epi-dihydroartemisinin
10-methoxy-1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane
10-Methoxy-1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane
159573-83-8
3,12-Epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-tri
71939-51-0
71963-77-4
74784-06-8
80286-56-2
93787-85-0
AC1L2APD
AC1L2XO8
AC1L9SH2
AC1L9UV0
AC1MI2ZX
AC1Q6Z74
AC1Q6Z7V
alpha-Artemether
alpha-Dihydroartemisinin methyl ether
AR-1A4424
Arteannuin ether
Artemetero
Artemetero [INN-Spanish]
Artemether
Artemether (INN)
Artemether [INN]
artemether, (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,12aR*))-isomer
artemether[inn]
Artemetheri
Artemetherum
Artemetherum [INN-Latin]
Artemisininelactol methyl ether
Artemos
Artenam
Artesaph
Artesian
Artimist
Artmether
b-Artemether
b-Dihydroartemisinin methyl ether
beta-Artemether
|
beta-Dihydroartemisinin methyl ether
BRN 5948416
C16H26O5
CHEBI:195280
CHEMBL411864
CHEMBL512315
CID10266705
CID104888
CID3062122
CID456408
CID500199
CID6483308
CID6712286
CID68911
CID9796294
CID9796295
CPD000469218
D02483
DB06697
dihydroartemisinin methyl ether
Dihydroartemisinin methyl ether
Dihydroqinghaosu methyl ether
Dihydroquinghaosu methyl ether
Falcidol
Gvither
HMS2052L09
HSDB 7456
I06-0205
KST-1A8041
LS-176935
LS-64237
Malartem
methyl-dihydroartemisinine
Methyl-dihydroartemisinine
MLS001424249
NCI60_022891
NSC 665970
NSC665970
O-Methyldihydroartemisinine
Paluther
rither
S2264_Selleck
SAM001246799
SM 224
SM 229
SM-224
SMR000469218
UNII-C7D6T3H22J
β-artemether
β-dihydroartemisinin methyl ether
|
|
5 |
|
Nitric Oxide |
Approved |
Phase 4 |
|
10102-43-9 |
145068 |
Synonyms:
(.)NO
(no)(.)
(NO)(.)
[no]
[NO]
10102-43-9
14332-28-6
295566_ALDRICH
51005-20-0
51005-21-1
53851-19-7
90452-29-2
AC1L1ADQ
AC1L3QHF
AC1Q6QZ0
AR-1K7463
Bioxyde d'azote
Bioxyde d'azote [French]
C00533
CCRIS 4319
CHEMBL1200689
CHEMBL1234765
CID145068
CID945
D00074
D009569
DB00435
EDRF
EINECS 233-271-0
Endogenous nitrate vasodilator
Endogenous Nitrate Vasodilator
Endothelium-derived nitric oxide
Endothelium-Derived Nitric Oxide
endothelium-derived relaxing factor
Endothelium-derived relaxing factor
HNO
HSDB 1246
INOmax
INOmax (TN)
LS-192158
LS-7547
MolPort-003-929-452
Mononitrogen monoxide
Monoxide, mononitrogen
Monoxide, Mononitrogen
Monoxide, nitrogen
Monoxide, Nitrogen
monoxido de nitrogeno
monoxido De nitrogeno
Monóxido de nitrógeno
monoxyde d'azote
Monoxyde d'azote
Nitrate vasodilator, endogenous
Nitrate Vasodilator, Endogenous
|
nitric oxide
Nitric oxide
Nitric oxide (JAN)
Nitric oxide 10% by volume or more
Nitric oxide trimer
Nitric oxide, compressed [UN1660] [Poison gas]
Nitric oxide, compressed [UN1660] [Poison gas]
Nitric oxide, endothelium derived
Nitric Oxide, Endothelium Derived
Nitric oxide, endothelium-derived
Nitric Oxide, Endothelium-Derived
NITRIC-OXIDE
nitrogen monooxide
Nitrogen monooxide
nitrogen monoxide
Nitrogen monoxide
Nitrogen oxide
Nitrogen oxide (NO)
Nitrogen protoxide
nitrosyl
Nitrosyl
Nitrosyl hydride
Nitrosyl hydride ((NO)H)
Nitrosyl radical
Nitroxide radical
Nitroxyl
NO
no(.)
NO(.)
OHM 11771
Oxide, nitric
Oxide, Nitric
oxido de nitrogeno(II)
oxido De nitrogeno(II)
óxido de nitrógeno(II)
oxido nitrico
oxido Nitrico
óxido nítrico
oxidonitrogen(.)
oxoazanyl
oxyde azotique
Oxyde azotique
Oxyde nitrique
Oxyde nitrique [French]
RCRA waste no. P076
Stickmonoxyd
Stickmonoxyd [German]
Stickstoff(II)-oxid
Stickstoffmonoxid
UN 1660
UN1660
UNII-31C4KY9ESH
Vasodilator, endogenous nitrate
Vasodilator, Endogenous Nitrate
|
|
6 |
|
Cefpirome |
Approved |
Phase 4 |
|
84957-29-9 |
5479539 |
Synonyms:
3-((2,3-cyclopenteno-1-Pyridinium)methyl)-7-(2-syn-methoximino-2-(2-aminothiazole-4-yl)acetamido)ceph-3-em-4-carboxylate
Cefir
cefpiroma
Cefpirome
Cefpirome sulfate
Cefpirome sulphate
|
cefpiromum
Cefrom
CPR
HR 810
Metran
|
|
7 |
|
Moxifloxacin |
Approved, Investigational |
Phase 4 |
|
354812-41-2, 151096-09-2 |
152946 |
Synonyms:
(1'S,6'S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
151096-09-2
186826-86-8
192927-63-2
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylate
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid
1-Cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
AC1L49EP
Actira
Actira (*Hydrochloride*)
Avalox
Avelox
Avelox (*Hydrochloride*)
Avelox I.V.
BAY 12-8039
BAY 12-8039 (*Hydrochloride*)
CCRIS 8690
|
CHEMBL32
CID152946
DB00218
I06-1961
Izilox
LS-141510
MFX
moxifloxacin
Moxifloxacin
Moxifloxacin [INN:BAN]
Moxifloxacin HCl
Moxifloxacin hydrochloride
Moxifloxacino
MXF
MXFX
Octegra
Proflox
UNII-U188XYD42P
Vigamox
|
|
8 |
|
Prilocaine |
Approved |
Phase 4 |
|
721-50-6 |
4906 |
Synonyms:
2-(propylamino)-O-Propionotoluidide
2-(Propylamino)-o-propionotoluidide
2-Methyl-.alpha.-propylaminopropionanilide
2-Methyl-alpha-propylaminopropionanilide
2-Methyl-a-propylaminopropionanilide
2-Methyl-α-propylaminopropionanilide
721-50-6
AB00053665
AC1L1J7W
AC-2100
alpha-n-Propylamino-2-methylpropionanilide
alpha-N-propylamino-2-Methylpropionanilide
Ambap1786-81-8
a-N-propylamino-2-Methylpropionanilide
Astra 1512
Astra 1515
Astra brand OF prilocaine hydrochloride
AstraZeneca brand OF prilocaine hydrochloride
BPBio1_000173
BRD-A53952395-003-05-3
BRN 2108498
BSPBio_000157
BSPBio_002604
C07531
C13H20N2O
CHEBI:8404
CHEMBL1194
CID4906
Citanest
Citanest octapressin
Citanest Plain
D00553
DB00750
Delvet brand OF prilocaine hydrochloride
DivK1c_000846
EINECS 211-957-0
HSDB 3386
I01-1860
IDI1_000846
Inibsa brand OF prilocaine hydrochloride
KBio1_000846
KBio2_002129
KBio2_004697
KBio2_007265
KBio3_001824
KBioGR_001883
KBioSS_002129
L 67
Lopac0_001005
|
LS-2304
MolPort-005-935-583
N-(2-Methylphenyl)-2-(propylamino)propanamide
N-(2-methylphenyl)-N(2)-propylalaninamide
N-(2-methylphenyl)-N2-propylalaninamide
N-[2-Methylphenyl]-2-[propylamino]propanamide
NCGC00015860-03
NCGC00162312-01
NINDS_000846
NSC 40027
NSC40027
o-Methyl-2-propylaminopropionanilide
O-Methyl-2-propylaminopropionanilide
o-Methyl-alpha-propylaminopropionanilide
O-Methyl-alpha-propylaminopropionanilide
O-Methyl-a-propylaminopropionanilide
O-Methyl-α-propylaminopropionanilide
Parnell brand OF prilocaine hydrochloride
Prestwick0_000199
Prestwick1_000199
Prestwick2_000199
Prestwick3_000199
Prilocain
Prilocaina
Prilocaina [INN-Spanish]
prilocaine
Prilocaine
Prilocaïne
Prilocaine (USP/INN)
Prilocaine [USAN]
prilocaine base
Prilocaine base
Prilocaine hydrochloride
Prilocainum
Prilocainum [INN-Latin]
Propanamide, N-(2-methylphenyl)-2-(propylamino)- (9CI)
Propitocaine
Propitocaine (JAN)
S1619_Selleck
SPBio_001398
SPBio_002078
Spectrum_001649
Spectrum2_001549
Spectrum3_001052
Spectrum4_001192
Spectrum5_001175
UNII-046O35D44R
Xylonest
α-N-propylamino-2-methylpropionanilide
|
|
9 |
|
Epinephrine |
Approved, Vet_approved |
Phase 4 |
|
51-43-4 |
5816 |
Synonyms:
(−)-(R)-epinephrine
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-a-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(−)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-Adrenalin
(−)-adrenaline
(-)-Adrenaline
(-)-Epinephrine
(-)-R-Epinephrine
(R)-(-)-Adnephrine
(R)-(−)-adrenaline
(R)-(-)-Adrenaline
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-Adrenaline
(R)-Epinephrine
02252_FLUKA
1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
1-Adrenalin
1-Epinephrine
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
51028-73-0
51-43-4
51-43-4 (FREE BASE)
A0173
AC-13188
AC1L1L7B
Acetate, epinephrine
Adnephrine
ADR ADRENALINE
Adrenal
Adrenalin
Adrenalin (TN)
Adrenalin in Oil
Adrenalina
Adrenalina [DCIT]
adrenaline
Adrenaline
Adrénaline
Adrenaline (JP15)
Adrenaline acid tartrate
Adrenaline bitartrate
Adrenaline hydrochloride
Adrenaline/Epinephrine
Adrenalin-Medihaler
Adrenalinum
Adrenamine
Adrenan
Adrenapax
Adrenasol
Adrenatrate
Adrenine
Adrenodis
Adrenohorma
Adrenosan
Adrenutol
Adrin
Adrine
ADROP
AI3-19015
Allergan brand OF adrenaline hydrochloride
Ana-Guard
Ana-kit
Antiasthmatique
Asmatane Mist
Asthma meter mist
Asthmahaler Mist
Asthmanefrin
Asthma-nefrin
Astmahalin
Astminhal
Balmadren
Bernarenin
BIDD:GT0119
Biorenine
bmse000316
Bosmin
Brevirenin
Bronkaid
Bronkaid mist
Bronkaid Mist
Bronkaid Suspension Mist
Bupivacaine Hcl and Epinephrine
C00788
CCRIS 4812
CHEBI:28918
Chelafrin
CHEMBL679
CID5816
Citanest Forte
Corisol
D00095
d-Adrenaline
DB00668
D-Epifrin
D-Epinephrine
Drenamist
Dylephrin
Dyspne-Inhal
E4250_SIGMA
EINECS 200-098-7
EPI E Z PEN JR
Epi EZ Pen Jr
Epifrin
Epiglaufrin
Epinefrin
Epinefrin [Czech]
Epinefrina
Epinefrina [INN-Spanish]
Epinephran
Epinephrin
epinephrine
Epinephrine
Epinephrine (USP)
Epinephrine (USP/INN)
Epinephrine [USAN:INN:JAN]
Epinephrine acetate
Epinephrine bitartrate
Epinephrine hydrochloride
Epinephrine hydrogen tartrate
Epinephrinum
Epinephrinum [INN-Latin]
Epipen
Epipen (TN)
Epipen Auto-Injector
EPIPEN E Z PEN
Epipen EZ Pen
Epipen JR
EPIPEN JR
|
Epipen Jr.
Epipen Jr. Auto-Injector
Epirenamine
Epirenan
Epirenin
Epitrate
Eppy
Esphygmogenina
Exadrin
Glaucon
Glaucosan
Glauposine
Glycirenan
Haemostasin
Haemostatin
Hektalin
Hemisine
Hemostasin
Hemostatin
HSCI1_000215
HSDB 4289
Hypernephrin
Hyporenin
Intranefrin
Iontocaine
IOP
Isoptoepinal
Kidoline
l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
l-Adrenalin
l-Adrenaline
L-Adrenaline
L-Adrenaline Base
L-Epinehphrine
l-Epinephine
L-epinephrine
L-Epinephrine
l-Epinephrine (synthetic)
l-Epirenamine
L-Epirenamine
Levoadrenaline
Levoepinephrine
Levo-Methylaminoethanolcatechol
Levorenen
Levorenin
Levorenine
Levoreninum
l-Methylaminoethanolcatechol
L-Methylaminoethanolcatechol
Lopac-E-4642
LS-156
Lyodrin
Lyophrin
Medihaler-epi
Medihaler-Epi
Metanephrin
Methylaminoethanolcatechol
Methylarterenol
Micronefrin
Micronephrine
MolPort-002-051-368
Mucidrina
Myosthenine
Mytrate
NCGC00015417-01
NCGC00142615-01
NCGC00142615-03
NCGC00142615-04
NCGC00142615-05
NCGC00142615-06
NCGC00142615-07
nchembio747-comp9
Nephridine
Nieraline
NSC 62786
NSC62786
Paranephrin
PDSP1_001120
PDSP2_001104
Primatene
Primatene mist
Primatene Mist
R-(-)-Epinephrine
Racemic Epinephrine
Racepinephrine
R-Adrenaline
RCRA waste no. P042
Rcra waste number P042
Renagladin
Renaglandin
Renaglandulin
Renaleptine
Renalina
Renoform
Renostypricin
Renostypticin
Renostyptin
Scurenaline
Septocaine
Simplene
Sindrenina
SMP1_000227
Soladren
Sphygmogenin
ST069368
Stryptirenal
Styptirenal
Supracapsulin
Supradin
Supranefran
Supranephrane
Supranephrine
Supranol
Suprarenaline
Suprarenin
Suprel
Surenine
Surrenine
Susphrine
Sus-phrine
Sus-Phrine
SUS-PHRINE SULFITE-FREE
Sympathin I
Takamina
Takamine
Tokamina
Tonogen
Twinject
Twinject 0.15
Twinject 0.3
Twinject 0.30
UNII-YKH834O4BH
Vaponefrin
Vasoconstrictine
Vasoconstrictor
Vasodrine
Vasoton
Vasotonin
|
|
10 |
|
Mannitol |
Approved, Investigational |
Phase 4 |
|
69-65-8 |
6251 453 |
Synonyms:
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
(L)-Mannitol
1,2,3,4,5,6-Hexanehexol
123897-58-5
133-43-7
15719_ALDRICH
15719_RIEDEL
33440_RIEDEL
33440_SIGMA
36413-61-3
4-01-00-02841 (Beilstein Handbook Reference)
5149-40-6
63559_FLUKA
63559_SIGMA
63560_FLUKA
63565_FLUKA
63565_SIGMA
69-65-8
75398-80-0
85085-15-0
87-78-5
AB1002081
AC-12776
AC1L1M49
AC1Q28E5
AI3-19511
Ambap69-65-8
AR-1J3861
bmse000099
BRN 1721898
C00392
C6H14O6
CCRIS 369
CHEBI:16899
CHEMBL689
CID6251
Cordycepate
Cordycepic acid
cpd without stereochemical designation
D-(-)-Mannitol
D00062
D008353
Diosmol
DL-Mannitol
D-mannite
D-mannitol
D-Mannitol
D-Mannitol (JP15)
Dulcite
e 421
e421
e-421
ED1D1E61-FEFB-430A-AFDC-D1F4A957FC3D
EINECS 200-711-8
EINECS 201-770-2
Hexahydroxyhexane
Hexanhexol
HSDB 714
Invenex
Isotol
LS-1588
LS-89250
M0044
M1902_SIGMA
M4125_SIAL
M8429_SIAL
|
M9546_SIAL
M9647_SIAL
Manicol
manita
Manitol
Maniton S
Maniton-S
Manna sugar
Manna Sugar
Mannazucker
Mannidex
Mannidex 16700
Mannigen
Mannistol
Mannit
Mannit P
Mannite
mannitol
Mannitol
Mannitol (USP)
Mannitol (VAN)
Mannitol [USAN]
Mannitol 10%
Mannitol 10% In Plastic Container
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER
Mannitol 15%
Mannitol 15% In Plastic Container
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%
Mannitol 20%
Mannitol 20% In Plastic Container
MANNITOL 25%
Mannitol 5%
Mannitol 5% In Plastic Container
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%
Mannitolum
Mannogem 2080
Marine crystal
Marine Crystal
MLS001335977
MLS001335978
MolPort-003-927-039
MTL
Mushroom sugar
NCGC00164246-01
NCI-C50362
NSC 407017
NSC 9256
Osmitrol
Osmitrol (TN)
Osmitrol 10% In Water
OSMITROL 10% IN WATER IN PLASTIC CONTAINER
Osmitrol 15% In Water
OSMITROL 15% IN WATER IN PLASTIC CONTAINER
Osmitrol 20% In Water
OSMITROL 20% IN WATER IN PLASTIC CONTAINER
Osmitrol 5% In Water
OSMITROL 5% IN WATER IN PLASTIC CONTAINER
Osmofundin
Osmosal
Resectisol
Resectisol In Plastic Container
SDM no. 35
SDM No. 35
SMR000857324
Sorbitol-Mannitol
SORBITOL-MANNITOL IN PLASTIC CONTAINER
TL806434
UNII-3OWL53L36A
ZINC02041302
|
|
11 |
|
Racepinephrine |
Approved |
Phase 4 |
|
329-65-7 |
838 |
Synonyms:
(+-)-Adrenaline
(+-)-Epinephrine
2-(methylamino)-1-(3,4-Dihydroxyphenyl)ethanol
Adrenaline hydrochloride, racemic mixture
Adrenaline, racemic
Adrenaline, racemic mixture
Bird brand OF racepinefrine hydrochloride
DL-Adrenaline
Epinephrine hydrochloride, racemic mixture
Epinephrine racemic
Epinephrine, racemic
Epinephrine, racemic mixture
Hydrochloride, racepinephrine
Micronefrin
|
Micronephrine
Mixture adrenaline, racemic
Mixture epinephrine, racemic
Racemic adrenaline
Racemic epinephrine
Racemic mixture adrenaline
Racemic mixture epinephrine
Racepinefrina
Racepinefrine
Racepinefrinum
Racepinephrine
Racepinephrine hydrochloride
Vaponefrin
|
|
12 |
|
Mycophenolic acid |
Approved |
Phase 4 |
|
24280-93-1 |
446541 |
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acid, mycophenolic
Acide mycophenolique
acido Micofenolico
Acido micofenolico
Acidum mycophenolicum
Melbex
|
micofenolico acido
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolic acid
Mycophenolsaeure
Mycophenolsäure
Myfortic
|
|
13 |
|
Azathioprine |
Approved |
Phase 4 |
|
446-86-6 |
2265 |
Synonyms:
[Methyl(nitroimidazolyl)mercaptopurine]
446-86-6
55774-33-9 (hydrochloride salt)
6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine
6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine
6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine
6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]
6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine
6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine
6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
6-(Methyl-p-nitro-5-imidazolyl)thiopurine
6-(Methyl-p-nitro-5-imidazolyl)-thiopurine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine
6-[(1-Methyl-4-nitroimidazol-5-yl)- thio] purine
6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine
6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine
A 4638
A2593_SIAL
A4638_SIAL
A4638_SIGMA
AB00443544
AB00443544-03
AC1L1DAL
AC1Q3Z1F
AC-4230
AI3-50290
AI-981/34845012
Azamun
Azamun [Czech]
Azanin
Azasan
Azasan (TN)
Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine
Azathioprin
azathioprine
Azathioprine
Azathioprine (JP15/USP/INN)
Azathioprine [USAN:INN:BAN:JAN]
Azathioprine sodium
Azathioprine Sodium
Azathioprine sodium salt
Azathioprine sulfate
Azathioprinum
Azathioprinum [INN-Latin]
Azathiopurine
azatiopr in
Azatioprin
Azatioprina
Azatioprina [INN-Spanish]
Azothioprine
B. W. 57-322
BPBio1_000054
BRD-K32821942-001-05-6
BRD-K60324116-001-01-5
BSPBio_000048
BSPBio_001876
BW 57322
BW 57-322
BW-57-322
C06837
C9H7N7O2S
CAS-446-86-6
CBDivE_013132
CCRIS 62
Ccucol
CHEBI:2948
CHEMBL1542
ChemDiv1_002659
CID2265
cMAP_000046
CPD000427366
Cytostatics
D00238
DB00993
DivK1c_000586
|
EINECS 207-175-4
EU-0100027
FT-0083532
HMS1568C10
HMS1920E17
HMS2091K19
HMS501N08
HMS594I19
HSDB 7084
IDI1_000586
Immuran
Imuran
Imuran (TN)
Imurek
Imurel
KBio1_000586
KBio2_000464
KBio2_002427
KBio2_003032
KBio2_004995
KBio2_005600
KBio2_007563
KBio3_001376
KBio3_002906
KBioGR_000646
KBioGR_002427
KBioSS_000464
KBioSS_002433
Lopac0_000027
Lopac-A-4638
LS-123
Methylnitroimidazolylmercaptopurine
MLS001049307
MolPort-000-745-914
MolPort-000-764-262
MolPort-003-665-485
Muran
NCGC00015060-01
NCGC00015060-02
NCGC00015060-04
NCGC00015060-12
NCGC00090836-01
NCGC00090836-02
NCGC00090836-03
NCGC00090836-04
NCGC00090836-05
NCGC00090836-06
NCGC00094593-01
NCGC00094593-02
NCGC00094593-03
NCI-C03474
NINDS_000586
NSC 39084
NSC39084
NSC-39084
Oprea1_375441
Oprea1_533384
Oprea1_633462
Prestwick_41
Prestwick0_000094
Prestwick1_000094
Prestwick2_000094
Prestwick3_000094
S1721_Selleck
SAM002589938
SDCCGMLS-0065415.P001
SMR000427366
Sodium, azathioprine
SPBio_000255
SPBio_001987
Spectrum_000064
SPECTRUM1500133
Spectrum2_000068
Spectrum3_000308
Spectrum4_000243
Spectrum5_000848
STK831906
STOCK1S-20293
STOCK1S-27186
Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl)
UNII-MRK240IY2L
WLN: T56 BM DN FN HNJ IS- ET5N CNJ A1 DNW
ZINC04258316
|
|
14 |
|
Ritonavir |
Approved, Investigational |
Phase 4 |
|
155213-67-5 |
392622 |
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
538, ABT
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
A-84538
Abbott 84538
ABBOTT-84538
ABT 538
ABT 84538
ABT538
ABT-538
AC1L94GB
AC-733
AKOS000280930
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
DB00503
|
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
NSC693184
RIT
ritonavir
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
RTV
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
|
|
15 |
|
Tacrolimus |
Approved, Investigational |
Phase 4 |
|
104987-11-3 |
445643 439492 6473866 |
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
Advagraf
AKOS005145901
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
Anhydrous, tacrolimus
BCBcMAP01_000194
Bio-0921
Bio2_000470
Bio2_000950
BRD-K35452788-001-02-1
BSPBio_001279
BSPBio-001279
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
Cilag brand OF tacrolimus
CPD000466356
CPD-10016
D08556
DB00864
DivK1c_001040
FK 506
FK5
Fk-506
FK506
FK-506
FR 900506
FR900506
|
FR-900506
FT-0082660
Fujimycin
Fujisawa brand OF tacrolimus
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
Janssen brand OF tacrolimus
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
nchembio.2007.23-comp2
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Prograft
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
tacrolimus
Tacrolimus
Tacrolimus (anhydrous)
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus anhydrous
tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
|
|
16 |
|
Metformin |
Approved |
Phase 4 |
|
657-24-9 |
14219 4091 |
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
cMAP_000016
D04966
DB00331
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMGG
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
Haurymelin
HMS2089D19
HSCI1_000295
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
|
KBioSS_002312
LA-6023
LS-43899
Melbin
metformin
Metformin
Metformin (USAN/INN)
Metformin [USAN:INN:BAN]
Metformin HCL
metformin hydrochloride
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
Sandoz Metformin
Siofor
SPBio_001928
STK011633
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
|
|
17 |
|
Desogestrel |
Approved |
Phase 4 |
|
54024-22-5 |
40973 |
Synonyms:
(17alpha)-13-Ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol
(8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol
13 Ethyl 11 methylene 18,19 dinor 17 alpha pregn 4 en 20 yn 17 ol
13-Ethyl-11-methylene-18,19-dinor-17 alpha-pregn-4-en-20-yn-17-ol
13-Ethyl-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-17-ol
13-Ethyl-11-methylene-18,19-dinor-17a-pregn-4-en-20-yn-17-ol
13-Ethyl-11-methylene-18,19-dinor-17α-pregn-4-en-20-yn-17-ol
17alpha-ethynyl-11-methylidene-18a-homo-estr-4-en-17beta-ol
54024-22-5
AC1L24T4
AC1Q282A
AC-308
alpha-pregn-4-en-20-yn-17-ol, 13-Ethyl-11-methylene-18,19-dinor-17
alpha-Pregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-18,19-dinor-17
C07629
C22H30O
Cerazette
CHEBI:4453
CHEMBL1533
CID40973
D017135
D02367
DB00304
|
desogen
Desogestrel
DESOGESTREL
Désogestrel
Desogestrel (USAN/INN)
Desogestrel [USAN:BAN:INN]
Desogestrelum
Desogestrelum [INN-Latin]
EINECS 258-929-4
HSDB 3593
LMST02030104
LS-62079
Marvelon
MolPort-003-846-424
NCGC00167449-01
ORG 2969
Org2969
Org-2969
Organon brand OF desogestrel
Organon Brand of Desogestrel
UNII-81K9V7M3A3
ZINC04097416
|
|
18 |
|
Etonogestrel |
Approved, Investigational |
Phase 4 |
|
54048-10-1 |
40976 6917715 |
Synonyms:
(8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
13-Ethyl-17-hydroxy-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one
17alpha-ethynyl-17beta-hydroxy-11-methylidene-18a-homo-estr-4-en-3-one
3-keto-Desogestrel
3-Ketodesogestrel
3-oxo Desogestrel
3-Oxodesogestrel
54048-10-1
AC1OCEK1
CHEBI:50777
CHEMBL1531
CID6917715
D04104
Etonogestrel
|
ETONOGESTREL
étonogestrel
Etonogestrel (USAN/INN)
etonogestrelum
Etonogestrelum
Implanon
Implanon (TN)
MolPort-003-847-336
NCGC00168777-01
Nexplanon
Nourypharma brand OF 3-keto-desogestrel
Org-3236
Organon brand OF 3-keto-desogestrel
ZINC11680067
|
|
19 |
|
Sotalol |
Approved |
Phase 4 |
|
3930-20-9, 959-24-0 |
5253 |
Synonyms:
.beta.-Cardone
27948-47-6
3930-20-9
4'-(1-hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide
4'-(1-Hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide
4'-(1-Hydroxy-2-(isopropylamino)ethyl)methane sulphonanilide
4'-(1-Hydroxy-2-isopropylaminoethyl)methanesulfonanilid
959-24-0 (mono-hydrochloride)
AB00514715
AC-19021
AC1L1JXU
b-Cardone
beta-Cardone
Betapace
Betapace AF
BPBio1_001069
BRD-A33168282-003-03-2
BSPBio_000971
C07309
C12H20N2O3S
CCRIS 4204
CHEMBL471
CID5253
d,l-Sotalol
D08525
Darob
Darob mite
Darob mite (TN)
DB00489
HMS2089K09
Knoll pharmaceutical brand OF sotalol
L013427
|
Lopac0_001055
LS-90249
Methanesulfonamide, N-(4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)phenyl)- (9CI)
MJ-1999
MolPort-002-042-381
N-(4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}phenyl)methanesulfonamide
N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide
N-{4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl}methanesulfonamide
NCGC00015919-05
NCGC00024899-02
NCGC00024899-03
Prestwick0_000966
Prestwick1_000966
Prestwick2_000966
Prestwick3_000966
SBB066409
Sorine
sotalol
Sotalol
Sotalol (INN)
Sotalol [INN:BAN]
Sotalol HCL
Sotalol hydrochloride
Sotalol monohydrochloride
Sotalol Monohydrochloride
Sotalolo
Sotalolum
Sotalolum [INN-Latin]
SPBio_002892
UNII-A6D97U294I
β-cardone
|
|
20 |
|
Bilirubin |
|
Phase 4 |
|
69853-43-6, 635-65-4 |
21252250 5280352 |
Synonyms:
(4E)2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo--21H-biline-8,12-dipropanoate
(4E)2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo--21H-biline-8,12-dipropanoic acid
|
|
|
21 |
|
Immunoglobulins |
|
Phase 4 |
|
|
|
22 |
|
Antibodies |
|
Phase 4 |
|
|
|
23 |
|
Immunoglobulins, Intravenous |
|
Phase 4 |
|
|
|
24 |
|
Antirheumatic Agents |
|
Phase 4 |
|
|
|
25 |
|
Interferon-alpha |
|
Phase 4 |
|
|
|
26 |
|
interferons |
|
Phase 4 |
|
|
|
27 |
|
Artemether, Lumefantrine Drug Combination |
|
Phase 4 |
|
|
|
28 |
|
Interferon alpha-2 |
|
Phase 4 |
|
|
|
29 |
|
Rho(D) Immune Globulin |
|
Phase 4 |
|
|
|
30 |
|
gamma-Globulins |
|
Phase 4 |
|
|
|
31 |
|
Norgestimate, ethinyl estradiol drug combination |
|
Phase 4 |
|
|
|
32 |
|
Epinephryl borate |
|
Phase 4 |
|
|
|
33 |
|
diuretics |
|
Phase 4 |
|
|
|
34 |
|
Elbasvir-grazoprevir drug combination |
|
Phase 4 |
|
|
|
35 |
|
MK-5172 |
|
Phase 4 |
|
|
|
36 |
|
Antitubercular Agents |
|
Phase 4 |
|
|
|
37 |
|
Calcineurin Inhibitors |
|
Phase 4 |
|
|
|
38 |
|
Iron Chelating Agents |
|
Phase 4 |
|
|
|
39 |
|
Liver Extracts |
|
Phase 4 |
|
|
|
40 |
|
Hypoglycemic Agents |
|
Phase 4 |
|
|
|
41 |
|
Progestins |
|
Phase 4 |
|
|
|
42 |
|
Contraceptive Agents |
|
Phase 4 |
|
|
|
43 |
|
Ethylene |
|
Phase 4 |
|
74-85-1 |
6325 |
Synonyms:
Acetene
Aethen
Aethylen
Athylen
Bicarburretted hydrogen
CH2=ch2
Elayl
Ethene
Ethene (9ci)
Ethene, 9ci
Ethylene
Ethylene (8ci)
|
Ethylene, compressed
Ethylene, pure
Ethylene-CMPD
Etileno
H2C=ch2
Liquid ethyene
Liquid ethylene
Olefiant gas
Plastipore
Polyethylene as med mol. wt.
R-1150
|
|
44 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
45 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
46 |
|
Sympatholytics |
|
Phase 4 |
|
|
|
47 |
|
Sodium Channel Blockers |
|
Phase 4 |
|
|
|
48 |
|
Adrenergic Antagonists |
|
Phase 4 |
|
|
|
49 |
|
Anti-Arrhythmia Agents |
|
Phase 4 |
|
|
|
50 |
|
Adrenergic beta-Antagonists |
|
Phase 4 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 159)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Investigation of Signal Pathway Induced by Colla Corri Asini Regulating Globin Level in Beta Thalassemia Patients With Pregnancy Anemia |
Unknown status |
NCT03392298 |
Phase 4 |
Colla corii asini |
2 |
A Multicenter Study to Evaluate the Efficacy of Yinzhihuang Oral Liquid on Indirect Bilirubin of Neonates With Glucose-6-phosphate Dehydrogenase Deficiency |
Unknown status |
NCT02594904 |
Phase 4 |
Yinzhihuang Oral Liquid |
3 |
Low Dose Peginterferon and Ribavirin Therapy for Patients With Chronic Hepatitis C Infected With Genotype 2 or 3 |
Completed |
NCT00056862 |
Phase 4 |
Peginterferon alfa-2a;Peginterferon alfa-2a;Ribavirin |
4 |
Efficacy and Safety of a Single Low-dose Primaquine Added to Standard Artemether-lumefantrine Treatment for the Clearance of Plasmodium Falciparum Gametocytes. |
Completed |
NCT02090036 |
Phase 4 |
Primaquine (For artemether-lumefantrine+primaquine arm);Placebo (For artemether-lumefantrine arm) |
5 |
Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin Versus Pegylated Interferon Alfa-2a Alone for Treatment-naïve Hemodialysis Patients With Chronic Hepatitis C |
Completed |
NCT00491244 |
Phase 4 |
Peginterferon alfa-2a and ribavirin;Peginterferon alfa-2a |
6 |
Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin Who Fail Interferon Alfa or Pegylated Interferon Alfa Monotherapy - a Pilot Study |
Completed |
NCT00491179 |
Phase 4 |
Pegylated interferon alfa-2a and ribavirin;Pegylated interferon alfa-2a and ribavirin |
7 |
A Pilot Study in Comparing the Efficacy and Safety of Peginterferon Alfa-2a and Interferon Alfa-2a in Treating Patients With End Stage Renal Disease and Chronic Hepatitis C |
Completed |
NCT00172809 |
Phase 4 |
Peginterferon alfa-2a;Interferon alfa-2a |
8 |
Combination of Pegylated Interferon and Ribavirin as Therapy for Patients With Chronic Hepatitis C With and Without Renal Disease |
Completed |
NCT00028093 |
Phase 4 |
Peginterferon alfa-2a with Ribavirin;Peginterferon alfa-2a |
9 |
Long-Term Therapy With Ribavirin for Chronic Hepatitis C |
Completed |
NCT00001854 |
Phase 4 |
Ribavirin |
10 |
Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration |
Completed |
NCT00280514 |
Phase 4 |
cefpirome and moxifloxacin administration |
11 |
Phase 4 Study of Use of High-dose Intravenous Immune Globulin for Prevent Hyperbilirubinemia Due Rh Hemolytic Disease in Newborns Infants |
Completed |
NCT00288600 |
Phase 4 |
Intravenous Immunoglobulin;Normal saline solution |
12 |
Evaluation of Ureteral Patency in the Post-indigo Carmine Era |
Completed |
NCT02677623 |
Phase 4 |
Pyridium;Sodium Fluorescein;Mannitol |
13 |
Elbasvir/Grazoprevir for Treatment-naive and Treatment-experienced Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis |
Completed |
NCT03420300 |
Phase 4 |
EBR/GZR |
14 |
A Randomized, Prospective, Multicenter Trial to Compare the Effect on Chronic Allograft Nephropathy Prevention of Mycophenolate Mofetil Versus Azathioprine as the Sole Immunosuppressive Therapy for Kidney Transplant Recipients |
Completed |
NCT00494741 |
Phase 4 |
mycophenolate mofetil;azathioprine |
15 |
Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for Treatment-Naive and Treatment-Experienced Non-Cirrhotic Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis |
Completed |
NCT02874066 |
Phase 4 |
PTV/r/OBV/DSV |
16 |
Tacrolimus Treatment for Refractory Autoimmune Cytopenia |
Recruiting |
NCT03918265 |
Phase 4 |
Tacrolimus |
17 |
A Multi-center Randomized, Double-blind, Placebo-controlled Study of Colla Corii Asini for the Treatment of Anemia in Pregnant Women With Thalassemia(Presenting the Syndrome of Blood Deficiency) |
Recruiting |
NCT03374111 |
Phase 4 |
Colla corii asini;a Simulate Agent of Colla corii asini granule |
18 |
The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalasemia Major |
Recruiting |
NCT02984475 |
Phase 4 |
Metformin |
19 |
Use of Etonogestrel-releasing Contraceptive Implant in Women With Sickle Cell Disease |
Active, not recruiting |
NCT02594462 |
Phase 4 |
etonogestrel-releasing implant contraceptive |
20 |
A Prospective, Multi-Center, Randomized, Open Label Trial to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs |
Not yet recruiting |
NCT02347111 |
Phase 4 |
Flecainide;Sotalol |
21 |
Anti-CD20 Antibody Rituximab in Addition to Prednisolone in Treatment of Warm Antibody Related Autoimmune Hemolytic Anemia. A Randomised Danish Multicenter Trial. |
Completed |
NCT01134432 |
Phase 3 |
prednisolone + mabthera;Prednisolone |
22 |
Low Doses of Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias |
Completed |
NCT00749112 |
Phase 2, Phase 3 |
Alemtuzumab, Rituximab |
23 |
Rituximab in Adult's Warm Auto-Immune Hemolytic Anemia : a Phase III, Double-bind, Randomised Placebo-controlled Trial |
Completed |
NCT01181154 |
Phase 3 |
rituximab (Mabthera®);Placebo |
24 |
Combination of Alpha Interferon With Long Term Ribavirin Therapy for Patients With Chronic Hepatitis C |
Completed |
NCT00001729 |
Phase 3 |
Ribavirin |
25 |
Minimally Invasive Management of Rh Alloimmunization: Can Amniotic Fluid DeltaOD450 Measurements Be Replaced by Doppler Studies? |
Completed |
NCT00295516 |
Phase 3 |
|
26 |
An Open-label, Randomized Pilot Study to Compare the Effectiveness of Peginterferon-alfa-2b Plus Ribavirin to Peginterferon-alfa-2b Plus Epoetin-alfa and Two Doses of Ribavirin in the Treatment of Chronic Hepatitis C Virus Infection |
Completed |
NCT00248339 |
Phase 3 |
Peginterferon-alpha-2b (PEG-Intron);Ribavirin;Epoetin-alpha (Procrit) |
27 |
Single-agent Rituximab as Maintenance Treatment Versus Observation After Combined Induction Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab in Patients Older Than 65 Years With Previously Untreated Chronic Lymphocytic Leukemia: a Phase III Trial of FILO |
Completed |
NCT00645606 |
Phase 3 |
|
28 |
Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo |
Completed |
NCT02205541 |
Phase 3 |
Eculizumab;Placebo |
29 |
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia |
Recruiting |
NCT03764618 |
Phase 3 |
Fostamatinib disodium;Placebo |
30 |
An Open-Label, Multicenter, Extension Study of AG-348 in Adult Subjects With Pyruvate Kinase Deficiency Previously Enrolled in AG-348 Studies |
Recruiting |
NCT03853798 |
Phase 3 |
AG-348 |
31 |
Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE) |
Recruiting |
NCT04084080 |
Phase 3 |
|
32 |
A Double-blind, Placebo-controlled, Adaptive, Phase 2/3 Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of INM004 in Pediatric Patients With Shiga Toxin-positive Bloody Diarrhea for Prevention of Hemolytic Uremic Syndrome |
Recruiting |
NCT04132375 |
Phase 2, Phase 3 |
INM004;Placebo |
33 |
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia |
Active, not recruiting |
NCT04138927 |
Phase 3 |
Fostamatinib disodium |
34 |
An Open-Label Study To Evaluate the Efficacy and Safety of AG-348 in Regularly Transfused Adult Subjects With Pyruvate Kinase (PK) Deficiency |
Active, not recruiting |
NCT03559699 |
Phase 3 |
AG-348 |
35 |
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion |
Active, not recruiting |
NCT03347422 |
Phase 3 |
Sutimlimab;Placebo |
36 |
A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion |
Active, not recruiting |
NCT03347396 |
Phase 3 |
Sutimlimab |
37 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Subjects With Pyruvate Kinase Deficiency |
Active, not recruiting |
NCT03548220 |
Phase 3 |
AG-348;Placebo |
38 |
An Open Label Extension Study of Voxelotor (GBT440) Administered Orally to Participants With Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials |
Active, not recruiting |
NCT03573882 |
Phase 3 |
Voxelotor |
39 |
Randomized Trial: Maternal Vitamin D Supplementation to Prevent Childhood Asthma (VDAART) |
Active, not recruiting |
NCT00920621 |
Phase 3 |
|
40 |
Sirolimus Combined With All Trans Retinoic Acid for the Treatment of Auto-Immune Anemia |
Not yet recruiting |
NCT04324411 |
Phase 2, Phase 3 |
sirolimus and ATRA |
41 |
Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope |
Not yet recruiting |
NCT04361318 |
Phase 2, Phase 3 |
|
42 |
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study |
Suspended |
NCT04119050 |
Phase 2, Phase 3 |
M281;Placebo |
43 |
High-dose Versus Standard-dose Weight-based Ribavirin in Combination With Peginterferon Alfa-2a for Patients Infected With Hepatitis C Virus Genotype 1 or 4 |
Terminated |
NCT00662220 |
Phase 3 |
ribavirin;ribavirin |
44 |
Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia. |
Unknown status |
NCT01579110 |
Phase 2 |
levamisole;Prednisone |
45 |
Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013) |
Unknown status |
NCT01760096 |
Phase 2 |
Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids |
46 |
Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria |
Unknown status |
NCT01642979 |
Phase 2 |
Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids |
47 |
Phase II Randomized Double-Blind Placebo-Controlled Trial of the Omega-3 Fatty Acids Eicosapentaenoic (EPA) and Docosahexaenoic Acid (DHA) in Pediatric Sickle Cell Disease (SCD) |
Unknown status |
NCT01202812 |
Phase 2 |
|
48 |
Prevention of Chikungunya Infection in Neonates: Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins |
Unknown status |
NCT02230163 |
Phase 1, Phase 2 |
|
49 |
Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease |
Completed |
NCT00010387 |
Phase 2 |
cyclophosphamide;filgrastim |
50 |
A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia |
Completed |
NCT01345708 |
Phase 2 |
prednisone, low dose rituximab |
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
alpha-Tocopherol Acetate
d-alpha-Tocopheryl Acetate
dl-alpha tocopheryl acetate
Tocopherol Acetate
TOCOPHEROL,DL-ALPHA
|
Tocopherols
TOCOPHERYL ACID SUCCINATE
TOCOPHERYL ACID SUCCINATE,D-ALPHA
Vitamin E
|
Cell-based therapeutics:
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Hemolytic Anemia:
Embryonic/Adult Cultured Cells Related to Hemolytic Anemia:
|